.png)
Irreversible Electroporation (IRE) Ablators are specialized medical devices that use precisely targeted electrical pulses to destroy cancerous tumors while preserving surrounding healthy tissues, nerves, and vital structures. IRE is a non-thermal ablation technique, making it particularly useful for tumors that are difficult to treat with heat-based methods like radiofrequency or microwave ablation.
In 2025, IRE Ablators are increasingly used in treating liver, pancreatic, kidney, and prostate cancers. Clinical trials show that over 78% of patients undergoing IRE procedures report improved local tumor control in anatomically challenging areas. As awareness grows, hospitals are investing in advanced electroporation equipment to offer patients a minimally invasive option for tumors near major blood vessels.
Irreversible Electroporation Ablators Market was valued at USD 29.47 million in 2023 and is projected to reach USD 32.85 million in 2024, with growth expected to reach USD 78.26 million by 2032, reflecting a CAGR of 11.46% during the forecast period [2024-2032].
How Big is the Irreversible Electroporation Ablators Industry in 2025?
The global IRE Ablators market is projected to expand steadily through 2025, driven by rising cancer incidence rates, advancements in image-guided interventions, and increasing demand for minimally invasive procedures.
It’s estimated that by the end of 2025, more than 45,000 IRE procedures will be performed worldwide annually — an increase of nearly 25% compared to five years ago. About 38% of these procedures target liver tumors, while pancreatic and prostate cancer applications make up 32% and 20% respectively.
Hospitals in North America account for nearly 42% of the total global procedure volume, with leading cancer centers adopting IRE as an option for patients ineligible for surgery. Europe represents around 28%, with Germany and the UK at the forefront, followed by Asia Pacific with 25%, driven by growing installations in advanced oncology centers across China, Japan, and South Korea.
As new generations of pulsed electric field generators and precision probes come to market, procedural success rates are expected to improve, helping clinicians achieve tumor control with minimal collateral damage.
Global Distribution of Irreversible Electroporation Ablators Manufacturers by Country in 2025
Manufacturers of IRE Ablators are concentrated in a few key med-tech innovation hubs. In 2025, North America holds about 40% of total IRE device production, led by pioneering firms like AngioDynamics and Pulse Biosciences. These companies invest heavily in R&D and clinical validation, ensuring a robust pipeline of next-generation devices.
Europe accounts for approximately 30%, with regional manufacturers and distributors supporting hospitals across the EU. Siric BRIO, based in Italy, is strengthening its footprint by partnering with teaching hospitals and oncology research groups to train specialists in IRE applications.
Asia Pacific represents about 25%, with countries like South Korea and Japan expanding their domestic med-tech manufacturing capabilities. BEX CO., LTD., headquartered in South Korea, is gaining ground by supplying affordable, advanced IRE systems to regional hospitals.
The remaining 5% of production is spread across Latin America and the Middle East, where medical device importers collaborate with global brands to supply major urban hospitals.
Regional Market Share: Irreversible Electroporation Ablators Regional Opportunities
North America
North America remains the largest and most mature market for IRE Ablators, accounting for roughly 44% of global usage in 2025. This region benefits from well-established cancer treatment centers and high patient awareness about non-thermal ablation options. Approximately 18,000 procedures are performed in the U.S. each year, primarily for liver and pancreatic tumors. Opportunities exist for local manufacturers to expand training programs, helping more interventional radiologists and oncologists adopt IRE in clinical practice.
Europe
Europe holds around 28% market share, driven by robust healthcare funding and cancer screening programs. Germany and the UK together perform about 9,000 IRE procedures annually, with liver and kidney applications leading demand. Regional distributors and OEMs are exploring public-private partnerships to equip smaller regional hospitals with cost-effective electroporation platforms.
Asia Pacific
Asia Pacific is witnessing fast growth and now makes up about 25% of global use, thanks to expanding oncology hubs in China, Japan, and South Korea. China alone accounts for nearly 8% of the global IRE procedure volume, supported by state investments in cutting-edge cancer centers. Growing demand for less invasive treatments is pushing local companies like BEX CO., LTD. to scale manufacturing and partner with large hospitals for pilot programs.
Latin America & MEA
Though relatively small in volume, Latin America and the Middle East & Africa represent untapped potential, together holding about 3% market share. Countries like Brazil, Saudi Arabia, and the UAE are investing in modern surgical technologies, opening opportunities for training surgeons in IRE techniques and partnering with global brands for supply chain resilience.
USA Growing Irreversible Electroporation Ablators Market
The USA continues to lead the world in adopting IRE Ablators, thanks to its advanced oncology infrastructure, favorable regulatory environment, and strong patient demand for organ-preserving procedures. More than 15,000 new IRE treatments are performed in the U.S. each year, representing over 35% of global usage.
Centers of Excellence in states like California, Texas, and New York are expanding IRE programs, offering patients options for tumors deemed inoperable by traditional surgery. University hospitals are also spearheading clinical trials to test IRE for other cancers, such as lung and bile duct tumors.
Manufacturers like AngioDynamics and Pulse Biosciences maintain robust U.S. distribution networks and collaborate with leading hospitals for product validation and training. As insurance coverage for IRE expands, procedural volumes are expected to increase, especially for high-risk patients who need a non-thermal alternative.
Global Growth Insights unveils the top List Global Irreversible Electroporation Ablators Companies:
| Company | Headquarters | 2024 CAGR | Revenue (Past Year) |
|---|---|---|---|
| AngioDynamics | Latham, New York, USA | 4.5% | USD 350 Million |
| Siric BRIO | Milan, Italy | 4.0% | USD 45 Million |
| BEX CO., LTD. | Seoul, South Korea | 4.8% | USD 32 Million |
| Pulse Biosciences | Hayward, California, USA | 5.0% | USD 75 Million |
CompanyHeadquarters2024 CAGRRevenue (Past Year)AngioDynamicsLatham, New York, USA4.5%USD 350 MillionSiric BRIOMilan, Italy4.0%USD 45 MillionBEX CO., LTD.Seoul, South Korea4.8%USD 32 MillionPulse BiosciencesHayward, California, USA5.0%USD 75 Million
Conclusion
The Irreversible Electroporation Ablators market in 2025 is poised for steady expansion as surgeons, oncologists, and interventional radiologists seek more targeted, tissue-preserving solutions for difficult-to-reach tumors. Key players like AngioDynamics, Pulse Biosciences, Siric BRIO, and BEX CO., LTD. continue to innovate, expand training programs, and strengthen hospital partnerships worldwide.
With rising patient awareness, better reimbursement, and advancements in pulse delivery technology, IRE Ablators are set to play an increasingly vital role in the global fight against cancer.
FAQs: Global Irreversible Electroporation Ablators Companies
Q1. What are Irreversible Electroporation Ablators?
They are non-thermal ablation systems that use pulsed electric fields to destroy cancer cells while sparing surrounding healthy tissue.
Q2. Which cancers are most treated with IRE?
Primarily liver, pancreatic, kidney, and prostate cancers, especially when tumors are near vital structures.
Q3. Who are the key manufacturers?
Major players include AngioDynamics, Pulse Biosciences, Siric BRIO, and BEX CO., LTD.
Q4. How big is the USA IRE market?
The USA accounts for about 35% of global procedures, with over 15,000 treatments annually.
Q5. What are the regional opportunities?
Asia Pacific and parts of Europe are expanding adoption, while Latin America and MEA present emerging markets for training and installations.